Changes in cell-free DNA after short-term palbociclib and fulvestrant treatment for advanced or metastatic hormone receptor-positive and human epidermal growth factor 2-negative breast cancer

被引：0

作者：

Takayuki Iwamoto

Naoki Niikura

Kenichi Watanabe

Takashi Takeshita

Yuichiro Kikawa

Kokoro Kobayashi

Nobutaka Iwakuma

Takuho Okamura

Hiroshi Tada

Shinji Ozaki

Toshitaka Okuno

Uhi Toh

Yutaka Yamamoto

Michiko Tsuneizumi

Hiroshi Ishiguro

Norikazu Masuda

Shigehira Saji

机构：

[1] Kawasaki Medical School Hospital,Breast and Thyroid Surgery

[2] Okayama University Hospital,Breast and Endocrine Surgery

[3] Tokai University School of Medicine,Department of Breast Oncology

[4] Hokkaido Cancer Center,Breast Surgery

[5] Kumamoto City Hospital,Breast and Endocrine Surgery

[6] Kansai Medical University Hospital,Department of Breast Surgery

[7] Saitama Red Cross Hospital,Department of Medical Oncology

[8] Kyushu Medical Center,Breast Center, Department of Breast Surgery

[9] Tohoku University Hospital,Department of Surgery, Division of Breast and Endocrine Surgery

[10] Hiroshima Prefectural Hospital,Department of Gastrointestinal and Breast Surgery

[11] Kobe City Nishi-Kobe Medical Center,Department of Breast Surgery

[12] Kurume University Hospital,Department of Breast Surgery

[13] Kumamoto University Hospital,Department of Breast and Endocrine Surgery

[14] Shizuoka General Hospital,Department of Breast Surgery

[15] Saitama Medical University International Medical Center,Breast Oncology Service

[16] Nagoya University Graduate School of Medicine,Department of Breast and Endocrine Surgery

[17] Fukushima Medical University School of Medicine,Department of Medical Oncology

来源：

Breast Cancer Research and Treatment | 2024年 / 203卷

关键词：

Advanced breast cancer; Palbociclib; Fulvestrant; Cell-free DNA; Window of opportunity;

D O I：

暂无

中图分类号：

学科分类号：

摘要：

引用

页码：225 / 234

页数：9

共 50 条

[41] Buparlisib plus fulvestrant versus placebo plus fulvestrant for postmenopausal, hormone receptor-positive, human epidermal growth factor receptor 2-negative, advanced breast cancer: Overall survival results from BELLE-2
Campone, Mario
Im, Seock-Ah
Iwata, Hiroji
Clemons, Mark
Ito, Yoshinori
Awada, Ahmad
Chia, Stephen
Jagiello-Gruszfeld, Agnieszka
Pistilli, Barbara
Tseng, Ling-Ming
Hurvitz, Sara
Masuda, Norikazu
Cortes, Javier
De Laurentiis, Michele
Arteaga, Carlos L.
Jiang, Zefei
Jonat, Walter
Le Mouhaer, Sylvie
Sankaran, Banu
Bourdeau, Laurence
El-Hashimy, Mona
Sellami, Dalila
Baselga, Jose
EUROPEAN JOURNAL OF CANCER, 2018, 103 : 147 - 154
[42] Palbociclib plus letrozole as first-line therapy in estrogen receptor-positive/human epidermal growth factor receptor 2-negative advanced breast cancer with extended follow-up
Rugo, H. S.
Finn, R. S.
Dieras, V.
Ettl, J.
Lipatov, O.
Joy, A. A.
Harbeck, N.
Castrellon, A.
Iyer, S.
Lu, D. R.
Mori, A.
Gauthier, E. R.
Bartlett, C. Huang
Gelmon, K. A.
Slamon, D. J.
BREAST CANCER RESEARCH AND TREATMENT, 2019, 174 (03) : 719 - 729
[43] Endocrine therapies in postmenopausal women with hormone receptor-positive, human epidermal growth factor receptor 2-negative, pretreated, advanced breast cancer A network meta-analysis
Lee, Cho-Hao
Kang, Yi-No
Ho, Ching-Liang
Lin, Chin
Chen, Po-Huang
Wu, Yi-Ying
Huang, Tzu-Chuan
MEDICINE, 2020, 99 (13) : E19618
[44] The efficacy of palbociclib and ribociclib in the first-line treatment of metastatic hormone receptor-positive, human epidermal growth factor receptor 2-negative breast cancer in male patients: a Turkish oncology group (TOG) study
Hasan Çağrı Yıldırım
Yasin Kutlu
Emel Mutlu
Musa Barış Aykan
Mustafa Korkmaz
Selim Yalçın
Teoman Şakalar
Özde Melisa Celayir
Erkan Kayıkçıoğlu
Ferit Aslan
Emre Hafızoğlu
Yunus Emre Altıntaş
Merve Keskinkılıç
Elvin Chalabiyev
Abdussamet Çelebi
Bengü Dursun
Caner Kapar
Miraç Özen
Ömer Acar
Özgecan Dülgar
Engin Kut
Sedat Biter
Fatih Kus
Elvina Almuradova
Atike Pınar Erdoğan
Seray Saray
Deniz Can Güven
Eda Tanrıkulu Şimşek
Necdet Üskent
Yasemin Kemal
Burcu Çakar
Özgür Açıkgöz
Saadettin Kılıçkap
Sercan Aksoy
International Journal of Clinical Oncology, 2024, 29 : 258 - 265
[45] The efficacy of palbociclib and ribociclib in the first-line treatment of metastatic hormone receptor-positive, human epidermal growth factor receptor 2-negative breast cancer in male patients: a Turkish oncology group (TOG) study
Yildirim, Hasan Cagri
Kutlu, Yasin
Mutlu, Emel
Aykan, Musa Baris
Korkmaz, Mustafa
Yalcin, Selim
Sakalar, Teoman
Celayir, Ozde Melisa
Kayikcioglu, Erkan
Aslan, Ferit
Hafizoglu, Emre
Altintas, Yunus Emre
Keskinkilic, Merve
Chalabiyev, Elvin
Celebi, Abdussamet
Dursun, Bengu
Kapar, Caner
Ozen, Mirac
Acar, Oemer
Dulgar, Ozgecan
Kut, Engin
Biter, Sedat
Kus, Fatih
Almuradova, Elvina
Erdogan, Atike Pinar
Saray, Seray
Guven, Deniz Can
Simsek, Eda Tanrikulu
Uskent, Necdet
Kemal, Yasemin
Cakar, Burcu
Acikgoz, Ozgur
Kilickap, Saadettin
Aksoy, Sercan
INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY, 2024, 29 (03) : 258 - 265
[46] Palbociclib plus letrozole as treatment for postmenopausal women with hormone receptor-positive/human epidermal growth factor receptor 2-negative advanced breast cancer for whom letrozole therapy is deemed appropriate: An expanded access study in Australia and India
Loi, Sherene
Karapetis, Christos S.
McCarthy, Nicole
Oakman, Catherine
Redfern, Andrew
White, Michelle
Khasraw, Mustafa
Doval, Dinesh Chandra
Gore, Vinod
Alam, Mahmood
Binko, Justin
Lu, Dongrui Ray
Kim, Sindy
Boyle, Frances
ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 2022, 18 (06) : 560 - 569
[47] Hormone Receptor-Positive/Human Epidermal Growth Receptor 2-Negative Metastatic Breast Cancer in Young Women: Emerging Data in the Era of Molecularly Targeted Agents
Shah, Ami N.
Metzger, Otto
Bartlett, Cynthia Huang
Liu, Yuan
Huang, Xin
Cristofanilli, Massimo
ONCOLOGIST, 2020, 25 (06) : E900 - E908
[48] Efficacy and safety of palbociclib in patients with estrogen receptor-positive/human epidermal growth factor receptor 2-negative advanced breast cancer with preexisting conditions: A post hoc analysis of PALOMA-2
Gelmon, Karen
Walshe, Janice M.
Mahtani, Reshma
Joy, Anil A.
Karuturi, Meghan
Neven, Patrick
Lu, Dongrui Ray
Kim, Sindy
Schnell, Patrick
Bananis, Eustratios
Schwartzberg, Lee
BREAST, 2021, 59 : 321 - 326
[49] Recent advances in the treatment of hormone receptor-positive/human epidermal growth factor 2-positive advanced breast cancer
Lv, Huimin
Yan, Min
Jiang, Zefei
THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY, 2021, 13
[50] Recent Advances in Adjuvant Endocrine Therapy in Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Breast Cancer
Cobain, Erin F.
Hayes, Daniel F.
JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (32) : 3673 - +

← 1 2 3 4 5 →